PROCEEDS WILL BE USED TO BRIDGE TO PAIN MANAGEMENT MEDICAL DEVICE COMMERCIALIZATION

Exhibit 10.3

For immediate release

               COMPETITIVE TECHNOLOGIES ENTERS INTO $8.0 MILLION
                        COMMON STOCK PURCHASE AGREEMENT

       PROCEEDS WILL BE USED TO BRIDGE TO PAIN MANAGEMENT MEDICAL DEVICE
                               COMMERCIALIZATION

FAIRFIELD,  CT  (AUGUST  6,  2008)  - COMPETITIVE TECHNOLOGIES, INC. (NYSE AMEX:
CTT),  announced  today  that  it  has entered into an $8.0 million common stock
purchase  agreement  with  Fusion  Capital  Fund  II,  LLC,  a  Chicago-based
institutional  investor.  Fusion  Capital  has  been  an  investor  in CTT since
February  2004 and has previously provided approximately $7.0 million in funding
to  the  company.  CTT may sell up to $8.0 million of its common stock to Fusion
Capital  from  time  to  time  over  a  25-month period after the Securities and
Exchange  Commission  has declared effective a registration statement related to
the  transaction.

"This  arrangement  will  provide  CTT  with needed bridge funding until we have
increased  revenue  from our exciting pain therapy medical device," said John B.
Nano, CTT's Chairman, President and CEO. "CTT is very pleased to again work with
Fusion  Capital."

CTT recently signed an agreement with Innovative Medical Therapies, Inc (IMT)
granting them exclusive distribution rights to CTT's pain therapy medical device
in the United States and related territories excluding selected Federal
agencies. The contract provides for minimum monthly cash payments to CTT
totaling over $1 million for the first five months. These minimum monthly
payments increase throughout the term of the agreement with the fourth year
minimum payments reaching $9 million and eighth year minimum payments of $21
million dollars. Seven sales agreements for the pain therapy medical device are
now in place for 42 countries around the world accounting for over 50% of the
world's population. CTT has exclusive worldwide rights to this device. The
device has U.S. FDA 510(k) clearance for U.S. sales, as well as Medical Device
CE certification from the E.U. allowing sales throughout Europe and several
other countries. Fusion Capital funding will help provide the necessary
resources for the global distribution ramp-up.

CTT recently announced that the U.S. Patent and Trademark Office's Board of
Patent Appeals and Interferences (BPAI) has uph